Document Detail

Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications.
MedLine Citation:
PMID:  17547875     Owner:  NLM     Status:  MEDLINE    
Severe preeclampsia that develops at <34 weeks of gestation is associated with high perinatal mortality and morbidity rates. Management with immediate delivery leads to high neonatal mortality and morbidity rates and prolonged hospitalization in the neonatal intensive care unit because of prematurity. Conversely, attempts to prolong pregnancy with expectant management may result in fetal death or asphyxial damage in utero and increased maternal morbidity. Since 1990, 2 randomized trials and several observational studies have evaluated the benefits vs risks of expectant management of severe preeclampsia at <34 weeks of gestation. These studies included 1677 women with gestational age between 24 and 34 weeks and 115 women with gestational age of <25 weeks (overlap in some studies). The results of these studies suggest that expectant treatment in a select group of women with severe preeclampsia between 24 0/7 and 32 6/7 weeks of gestation in a suitable hospital is safe and improves neonatal outcome. For gestational age of <24 0/7 weeks, expectant treatment was associated with high maternal morbidity with limited perinatal benefit. Based on the review of these studies and our own experience, recommendations are made for the selection of the appropriate candidates for expectant treatment, criteria for maternal-fetal monitoring, and targets for delivery. Finally, we provide information regarding maternal counseling based on maternal condition and fetal gestational age at time of diagnosis.
Baha M Sibai; John R Barton
Related Documents :
12047535 - Ultrasonographic evaluation of cervical length in pregnancies complicated by preterm pr...
9583075 - Staphylococcus aureus causing chorioamnionitis and fetal death with intact membranes at...
1698335 - Gram stain results from amniocentesis in patients with preterm premature rupture of mem...
7862375 - Uterine artery velocimetry and spontaneous preterm delivery.
18054005 - Successful pregnancy outcome after in vitro fertilization in a pancreas-kidney recipient.
18042995 - Pregnancy outcomes following bipolar umbilical cord cauterization for selective termina...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  196     ISSN:  1097-6868     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-06-05     Completed Date:  2007-10-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  514.e1-9     Citation Subset:  AIM; IM    
Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0526, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Anticonvulsants / therapeutic use
Antihypertensive Agents / therapeutic use
Decision Making
Delivery, Obstetric*
Fetal Monitoring
Magnesium Sulfate / therapeutic use
Patient Selection*
Pre-Eclampsia / therapy*
Randomized Controlled Trials as Topic
Severity of Illness Index
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Anticonvulsants; 0/Antihypertensive Agents; 7487-88-9/Magnesium Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  To the point: medical education reviews--providing feedback.
Next Document:  A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition o...